HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:NURS - CA44877L1013 - Common Stock
4.02 CAD
0 (0%)
NURS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 8 industry peers in the Health Care Technology industry. NURS has an average financial health and profitability rating. NURS is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year NURS was profitable.
In the past year NURS had a positive cash flow from operations.
1.2 Ratios
The Return On Assets of NURS (2.04%) is better than 100.00% of its industry peers.
NURS has a Return On Equity of 4.79%. This is amongst the best in the industry. NURS outperforms 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.46%, NURS belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.04% | ||
| ROE | 4.79% | ||
| ROIC | 1.46% |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NURS has a better Profit Margin (1.85%) than 87.50% of its industry peers.
NURS's Operating Margin of 1.48% is amongst the best of the industry. NURS outperforms 87.50% of its industry peers.
Looking at the Gross Margin, with a value of 29.16%, NURS is doing worse than 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of NURS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.48% | ||
| PM (TTM) | 1.85% | ||
| GM | 29.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NURS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for NURS has been increased compared to 1 year ago.
NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 10.83 indicates that NURS is not in any danger for bankruptcy at the moment.
NURS has a better Altman-Z score (10.83) than 75.00% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that NURS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.83, NURS is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.83 |
ROIC/WACC0.17
WACC8.71%
2.3 Liquidity
A Current Ratio of 4.47 indicates that NURS has no problem at all paying its short term obligations.
The Current ratio of NURS (4.47) is better than 87.50% of its industry peers.
NURS has a Quick Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 4.47, NURS belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.47 | ||
| Quick Ratio | 4.47 |
3. Growth
3.1 Past
NURS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 128.24%, which is quite impressive.
Looking at the last year, NURS shows a very strong growth in Revenue. The Revenue has grown by 59.17%.
Measured over the past years, NURS shows a very strong growth in Revenue. The Revenue has been growing by 137.35% on average per year.
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%
3.2 Future
NURS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 279.00% yearly.
The Revenue is expected to grow by 121.25% on average over the next years. This is a very strong growth
EPS Next Y682.69%
EPS Next 2Y388.37%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue Next Year192.73%
Revenue Next 2Y163.11%
Revenue Next 3Y121.25%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NURS is valuated quite expensively with a Price/Earnings ratio of 402.00.
Based on the Price/Earnings ratio, NURS is valued cheaper than 87.50% of the companies in the same industry.
NURS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.57.
The Price/Forward Earnings ratio is 17.69, which indicates a rather expensive current valuation of NURS.
NURS's Price/Forward Earnings ratio is rather cheap when compared to the industry. NURS is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, NURS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 402 | ||
| Fwd PE | 17.69 |
4.2 Price Multiples
NURS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NURS is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 298.67 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NURS's earnings are expected to grow with 279.00% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y388.37%
EPS Next 3Y279.01%
5. Dividend
5.1 Amount
NURS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:NURS (12/24/2025, 7:00:00 PM)
4.02
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners1.25%
Inst Owner ChangeN/A
Ins Owners2.13%
Ins Owner ChangeN/A
Market Cap199.35M
Revenue(TTM)24.48M
Net Income(TTM)453.30K
Analysts80
Price Target7.82 (94.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.44%
Min Revenue beat(2)-33.59%
Max Revenue beat(2)8.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.8%
PT rev (3m)-9.8%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-20%
EPS NY rev (1m)-33.33%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)-18.46%
Revenue NQ rev (3m)-29.6%
Revenue NY rev (1m)-9.58%
Revenue NY rev (3m)-21.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 402 | ||
| Fwd PE | 17.69 | ||
| P/S | 8.14 | ||
| P/FCF | N/A | ||
| P/OCF | 273.99 | ||
| P/B | 21.04 | ||
| P/tB | 27.81 | ||
| EV/EBITDA | 298.67 |
EPS(TTM)0.01
EY0.25%
EPS(NY)0.23
Fwd EY5.65%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.36%
SpS0.49
BVpS0.19
TBVpS0.14
PEG (NY)0.59
PEG (5Y)N/A
Graham Number0.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.04% | ||
| ROE | 4.79% | ||
| ROCE | 2.03% | ||
| ROIC | 1.46% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 1.48% | ||
| PM (TTM) | 1.85% | ||
| GM | 29.16% | ||
| FCFM | N/A |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 12.5 | ||
| Cap/Depr | 535.2% | ||
| Cap/Sales | 5.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 115.22% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.47 | ||
| Quick Ratio | 4.47 | ||
| Altman-Z | 10.83 |
F-Score5
WACC8.71%
ROIC/WACC0.17
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
EPS Next Y682.69%
EPS Next 2Y388.37%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%
Revenue Next Year192.73%
Revenue Next 2Y163.11%
Revenue Next 3Y121.25%
Revenue Next 5YN/A
EBIT growth 1Y124.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year633.54%
EBIT Next 3Y303.71%
EBIT Next 5YN/A
FCF growth 1Y46.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.05%
OCF growth 3YN/A
OCF growth 5YN/A
HYDREIGHT TECHNOLOGIES INC / NURS.CA FAQ
Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.
What is the valuation status for NURS stock?
ChartMill assigns a valuation rating of 5 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for HYDREIGHT TECHNOLOGIES INC?
HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 4 / 10.
Can you provide the financial health for NURS stock?
The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 5 / 10.
What is the expected EPS growth for HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?
The Earnings per Share (EPS) of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is expected to grow by 682.69% in the next year.